S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:ADVM

Adverum Biotechnologies (ADVM) Stock Price, News & Analysis

$14.14
-0.52 (-3.55%)
(As of 03/28/2024 ET)
Today's Range
$13.84
$14.82
50-Day Range
$8.48
$28.10
52-Week Range
$6.81
$29.70
Volume
109,875 shs
Average Volume
252,171 shs
Market Capitalization
$293.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.67

Adverum Biotechnologies MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
145.2% Upside
$34.67 Price Target
Short Interest
Healthy
4.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.78
Upright™ Environmental Score
News Sentiment
1.07mentions of Adverum Biotechnologies in the last 14 days
Based on 12 Articles This Week
Insider Trading
Acquiring Shares
$135,000 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.63 out of 5 stars

Medical Sector

67th out of 938 stocks

Biological Products, Except Diagnostic Industry

11th out of 148 stocks

ADVM stock logo

About Adverum Biotechnologies Stock (NASDAQ:ADVM)

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

ADVM Stock Price History

ADVM Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Adverum Biotechnologies (NASDAQ:ADVM) Shares Gap Down to $14.75
Adverum Biotechnologies (NASDAQ:ADVM) PT Lowered to $2.00
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Adverum Biotechnologies (ADVM) Receives a Buy from TD Cowen
ADVM Adverum Biotechnologies, Inc.
ADVM Apr 2024 5.000 call
Stocks on the Launchpad: The Next 3 Market Sensations
Unleash Massive Returns With These 3 Top Penny Stocks
ADVM Feb 2024 4.000 call
ADVM Sep 2024 2.500 put
Adverum Biotechnologies Inc (ADVM)
See More Headlines
Receive ADVM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adverum Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/18/2024
Today
3/29/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ADVM
Employees
121
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$34.67
High Stock Price Target
$60.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+145.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-117,170,000.00
Pretax Margin
-3,284.53%

Debt

Sales & Book Value

Annual Sales
$3.60 million
Book Value
$8.26 per share

Miscellaneous

Free Float
19,655,000
Market Cap
$293.41 million
Optionable
Optionable
Beta
0.88
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Laurent FischerDr. Laurent Fischer (Age 60)
    President, CEO & Director
    Comp: $1.02M
  • Ms. Linda M. Rubinstein M.A. (Age 57)
    CFO, Principal Financial Officer & Principal Accounting Officer
    Comp: $940.99k
  • Ms. Dena House
    Chief People Officer
  • Ms. Carla Fiankan
    Senior Vice President of Regulatory Affairs
  • Mr. Michael Steel
    Senior Vice President of Quality
  • Mr. Heikki Jouttijarvi
    Senior VP of Manufacturing & Supply Chain Management and Head of Technical Operations
  • Mr. Anand Reddi (Age 41)
    VP and Head of Corporate Strategy & External Affairs & Engagement
  • Dr. Bill Tan Pharm.D.
    Senior VP & Head of Global Clinical Operations
  • Dr. Kalliopi Stasi M.D.
    Ph.D., Senior Vice President of Clinical Development

ADVM Stock Analysis - Frequently Asked Questions

Should I buy or sell Adverum Biotechnologies stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADVM shares.
View ADVM analyst ratings
or view top-rated stocks.

What is Adverum Biotechnologies' stock price target for 2024?

3 brokerages have issued 12 month price objectives for Adverum Biotechnologies' stock. Their ADVM share price targets range from $4.00 to $60.00. On average, they expect the company's share price to reach $34.67 in the next twelve months. This suggests a possible upside of 145.2% from the stock's current price.
View analysts price targets for ADVM
or view top-rated stocks among Wall Street analysts.

How have ADVM shares performed in 2024?

Adverum Biotechnologies' stock was trading at $7.5280 at the beginning of 2024. Since then, ADVM stock has increased by 87.8% and is now trading at $14.14.
View the best growth stocks for 2024 here
.

Are investors shorting Adverum Biotechnologies?

Adverum Biotechnologies saw a drop in short interest in March. As of March 15th, there was short interest totaling 648,500 shares, a drop of 88.1% from the February 29th total of 5,430,000 shares. Based on an average trading volume of 231,700 shares, the days-to-cover ratio is currently 2.8 days. Currently, 4.3% of the shares of the stock are sold short.
View Adverum Biotechnologies' Short Interest
.

When is Adverum Biotechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ADVM earnings forecast
.

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) released its quarterly earnings results on Monday, March, 18th. The biotechnology company reported ($2.30) EPS for the quarter, beating analysts' consensus estimates of ($2.80) by $0.50.

When did Adverum Biotechnologies' stock split?

Shares of Adverum Biotechnologies reverse split on Thursday, March 21st 2024. The 1-10 reverse split was announced on Thursday, March 21st 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Laurent Fischer, M.D.'s approval rating as Adverum Biotechnologies' CEO?

3 employees have rated Adverum Biotechnologies Chief Executive Officer Laurent Fischer, M.D. on Glassdoor.com. Laurent Fischer, M.D. has an approval rating of 72% among the company's employees.

What other stocks do shareholders of Adverum Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Amarin (AMRN), Endologix (ELGX), Immunomedics (IMMU), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH) and Genocea Biosciences (GNCA).

Who are Adverum Biotechnologies' major shareholders?

Adverum Biotechnologies' stock is owned by a number of institutional and retail investors. Top institutional investors include BML Capital Management LLC (4.51%), AIGH Capital Management LLC (3.14%), Newtyn Management LLC (0.81%), Worth Venture Partners LLC (0.78%), Dimensional Fund Advisors LP (0.19%) and Twin Focus Capital Partners LLC (0.10%). Insiders that own company stock include Brigit Riley, Dawn Svoronos, James Paul Scopa, Julie Clark, Laurent Fischer, Peter Soparkar, Richard Beckman, Rupert D'souza and Setareh Seyedkazemi.
View institutional ownership trends
.

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADVM) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners